David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!
Per Wester - NOACs; advances and limitations in real world
New oral anticoagulants or NOACs, with favorable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. There are still limitations associated. Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible for treatment. The focus on NOACs has shifted to the practical approach and management in real life.
Holger Poppert - Stroke and bleeding risk stratification in AF from guideline to clinical practice
Broad based review, starting with the basic stroke risk management scores to bleeding risk scores towards expert knowledge and additional diagnostics to help define individual bleeding risk
John Camm - Contraindication to OAC dilemma; absolute or relative contraindication?
Contraindications to OAC: Which are the patients who cannot legitimately take anti-coagulants - who have adverse events and where it won't work."
Dorte Damgaard - Preventing & managing intracranial hemorrhage
The incidence of ICH has remained unchanged and prevention takes a higher priority, now that more patients are on OAC than before. The management of ICH involves admission to stroke units, BP lowering and reversal of OAC.
Eivind Berge - Patient management; when to stop or to re-start the oral anticaoagulation therapy?
The dilemma: should we start, or should we not start anti-coagulation therapy in patients with a prior intracranial hemorrhage and with AF?